Pfizer Inc. is a global biopharmaceutical company with a market cap of $138.2 billion. Despite its long history and broad range of therapeutic areas, its stock has underperformed the market. Recently, Pfizer announced a licensing deal with 3SBio for a cancer treatment, causing a slight drop in its shares.

Analysts expect Pfizer’s EPS to decline slightly this year, but the company has a history of beating estimates. The consensus rating among 22 analysts is a “Moderate Buy,” with a mix of ratings. UBS analyst Trung Huynh raised Pfizer’s price target, citing cost savings as a positive factor.

The mean price target for Pfizer suggests a 14.4% premium to current levels, with a high target indicating a 35.7% upside potential. Despite mixed revenue performance, analysts remain cautiously optimistic about Pfizer’s future.

Read more at Yahoo Finance: Pfizer Stock: Analyst Estimates & Ratings